trial · primary record
Ibrutinib
Chronic Lymphocytic Leukemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 23 |
| Primary completion | 2028-04 |
| Primary endpoint | Dose Limiting Toxicity (DLT) |
| Registry ID | NCT03153202 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:38.001Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03153202
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.